Publication: Evaluación de los usos de la finasterida en la práctica clínica y sus evidencias científicas
Loading...
Official URL
Full text at PDC
Publication Date
2015-06
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Citations
Exportar
Abstract
Introducción
La Finasterida es un inhibidor selectivo de la 5α-reductasa encargada de la conversión de testosterona en dihidrotestosterona (DHT), cuyo aumento produce hiperplasia benigna de próstata (HBP) y alopecia androgenética.
Objetivos
Reflejar la posible utilización de un mismo principio activo para dos indicaciones terapéuticas diferentes, así como revisar los estudios que pretenden plantear el uso de esta molécula con alguna indicación no registrada en sus fichas técnicas.
Material y métodos
Revisión de numerosos artículos contenidos en las bases de datos AEMPS, Micromedex® y Pubmed®.
Resultados y discusión
Se demostró el uso de Finasterida 5mg como tratamiento eficaz para el tratamiento de HBP. Además, se probó también el uso de Finasterida 1 mg en el tratamiento de la alopecia androgenética. Por último, no se obtuvieron conclusiones suficientes para afirmar que esta molécula podría tratar el hirsutismo, pero sí que podría reducir la incidencia de cáncer de próstata.
Conclusiones
Un mismo principio activo puede tratar dos patologías diferentes con el simple cambio de su posología. No existen evidencias que demuestren el tratamiento del hirsutismo con finasterida, pero sí que lo hacen como prevención en el tratamiento de cáncer de próstata aunque esta molécula pudiese agravar la patología si se produjese.
Introduction Finasteride is a selective 5-α reductase inhibitor. This enzyme transforms testosterone into DHT, which, when increased, causes Benign Prostate Hiperplasia and androgenética alopecia. Objectives Reflecting how just one active ingredient can be used in two different therapeutic indications as well as look over the researches which set out the use of this molecule to non-included in the FDA treatments. Materials and Methods Review of numerous articles contained in scientific databases such as Pubmed®, Micromedex® or AEMPS Results and Discussion The use of Finasteride 5mg was proved as an effective treatment against HBP. In addition, Finasteride was shown to be also effective in androgenetic alopecia treatment. Finally, there were not conclusive findings relating this molecule with hirsutism but evidence was found to conclude Finasterida could be preventive for Prostate Cancer decreasing its incidence. Conclusions The same active ingredient can be used in two different pathologies treatment. There is no evidence to show Finasteride can treat hirsutism. Some researches have concluded Finasteride could be an effective therapy in Prostate Cancer prevention, although this molecule could exacerbate this cancer gravity.
Introduction Finasteride is a selective 5-α reductase inhibitor. This enzyme transforms testosterone into DHT, which, when increased, causes Benign Prostate Hiperplasia and androgenética alopecia. Objectives Reflecting how just one active ingredient can be used in two different therapeutic indications as well as look over the researches which set out the use of this molecule to non-included in the FDA treatments. Materials and Methods Review of numerous articles contained in scientific databases such as Pubmed®, Micromedex® or AEMPS Results and Discussion The use of Finasteride 5mg was proved as an effective treatment against HBP. In addition, Finasteride was shown to be also effective in androgenetic alopecia treatment. Finally, there were not conclusive findings relating this molecule with hirsutism but evidence was found to conclude Finasterida could be preventive for Prostate Cancer decreasing its incidence. Conclusions The same active ingredient can be used in two different pathologies treatment. There is no evidence to show Finasteride can treat hirsutism. Some researches have concluded Finasteride could be an effective therapy in Prostate Cancer prevention, although this molecule could exacerbate this cancer gravity.